# OnCo record mifamurtide (drug). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix owl: <http://www.w3.org/2002/07/owl#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/drugs/mifamurtide/>
  a schema:Drug ;
  onco:kind "drug" ;
  schema:identifier "mifamurtide" ;
  schema:name "Mifamurtide"@en ;
  schema:description "An immune-activating drug approved in Europe for osteosarcoma after a trial suggested it improved survival; the FDA never approved it, and it remains one of oncology's transatlantic disagreements."@en ;
  schema:url <https://onco.cc/drugs/mifamurtide/> ;
  schema:dateModified "2026-09-08"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Mifamurtide> ;
  owl:sameAs <http://www.wikidata.org/entity/Q411175> ;
  schema:citation <https://www.ema.europa.eu/en/medicines/human/EPAR/mepact> ;
  onco:status "approved" ;
  onco:tag "gap-fill" ;
  onco:modality "Liposomal muramyl tripeptide (macrophage activator)" ;
  schema:alternateName "Mepact" ;
  onco:approval "EU 2009: High-grade resectable non-metastatic osteosarcoma after complete resection, with chemotherapy, ages 2-30" ;
  onco:cancers <https://onco.cc/cancers/osteosarcoma/> ;
  onco:technologies <https://onco.cc/technologies/cytokine-therapy/> ;
  onco:companies <https://onco.cc/companies/takeda/> ;
  onco:trials <https://onco.cc/trials/nct03643133/>, <https://onco.cc/trials/nct07787429/>, <https://onco.cc/trials/nct02441309/> .